Precision's Messerschmidt Discusses New Myeloma Therapies in Managed Healthcare Executive


In the current edition of Managed Healthcare Executive, Precision Oncology’s chief medical officer Dr. Gerry Messerschmidt comments on the unprecedented pace of outcomes improvements. “New therapies in myeloma are being approved and brought into investigation at an ever-increasing rate,” he notes.

To read the complete article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.